AIM ImmunoTech, Ampligen, Rintatolimod, Pancreatic Cancer, Metastatic Pancreatic Cancer, DURIPANC, Durvalumab, Imfinzi, AstraZeneca, TLR3, TLR3 Agonist,

OCALA, Fla. — October 7, 2026 AIM ImmunoTech highlighted its strategy to address treatment resistance in metastatic pancreatic cancer...